← Back to Deal Tracker
↗InvestmentVerified
BVF Partners
↓
Superluminal Medicines

Deal Value

Undisclosed

Announced

Thursday, September 3, 2026

Deal Details

Superluminal Medicines raised a $60 million Series B to advance AI- and ML-driven GPCR drug discovery, including a lead obesity program entering Phase 1.

A financial investment providing capital in exchange for equity or strategic partnership.

Related News

Superluminal Medicines raises $60M Series B for AI driven obesity drugs

On September 3, 2026 Superluminal Medicines announced a $60 million oversubscribed Series B round led by BVF Partners to advance its AI- and ML-enabled GPCR drug discovery platform. The Boston biotech plans to fund a Phase 1 trial for a rare genetic obesity program and expand its GPCR pipeline.

Sep 3, 2026
View Original Source↗
More Investment DealsBVF Partners DealsSuperluminal Medicines Deals

Related Deals

↗Investment

Delta-v Capital → HiddenLayer

UndisclosedSep 2, 2026
↗Investment

Breakthrough Energy Ventures → Physical Superintelligence

UndisclosedSep 2, 2026
↗Investment

Insight Partners → Wonderful

UndisclosedSep 2, 2026
↗Investment

Sequoia Capital → Empirik

UndisclosedSep 1, 2026
↗Investment

Sequoia Capital → AIR

UndisclosedSep 1, 2026
↗Investment

NextView Ventures → Fambot

UndisclosedSep 1, 2026